Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer

PRINCETON, NJ--(Marketwired - October 25, 2017) - Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious cutaneous oncology indications, announced today that it has appointed John Liatos as its Chief Financial Officer ("CFO").

"John is an excellent addition to our management team and joins Adgero at an exciting stage of the Company as we work to advance our lead product candidate, REM-001 Therapy, towards late stage clinical development and commercialization," commented Frank Pilkiewicz, Ph.D., President, CEO and Chairman of the Board of Adgero. "I believe that his broad operational and financial expertise combined with his strong business acumen will be invaluable as we work towards continuing the successful execution of our corporate and clinical milestones. We believe that our REM-001 Therapy has the potential to address an unmet need in the current standard of care for the treatment of serious cutaneous oncology indications and we look forward to leveraging the combined strength of each of the members of our management team."

Mr. Liatos joins Adgero with over 20 years of experience in operations, corporate finance, private equity and venture capital related to the life sciences industry. Prior to joining Adgero, Mr. Liatos was the Co-Founding Partner at Aceras BioMedical, LLC, a unique healthcare-focused investment firm focused on forming and managing new companies to acquire and develop pre-commercial stage biomedical assets. During his time at Aceras, Mr. Liatos was responsible for the overall formation and business strategy of Aceras and its portfolio companies, as well as evaluating new investments. Mr. Liatos served as the Co-founder and CFO of Huxley Pharmaceuticals, Inc., an Aceras portfolio company acquired by BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), as well as the Co-founder and CFO of Sherrington Pharmaceuticals, Inc., an Aceras portfolio company that develops specialty products for severe pain disorders which was acquired by Sorrento Therapeutics, Inc. (NASDAQ: SRNE). Mr. Liatos also served as the CFO of a life sciences investment fund, Paramount BioSciences, LLC, where his experience included management recruitment, deal structuring and negotiations, investment valuation, financial reporting and corporate transactions, including mergers and acquisitions, private placements and self-registrations for the Paramount portfolio companies. Prior to that, Mr. Liatos served as a Senior Associate at Gefinor (USA), Inc., a New York-based private equity firm and as a Senior Associate in the Financial Reporting and Consolidations group at RJR Nabisco, Inc.

Mr. Liatos earned his B.S. in Business Administration from The Citadel in Charleston, S.C. and began his career as an auditor at Eisner Amper LLP, formerly known as Richard A. Eisner & Company, a regional public accounting firm.

About Adgero

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious cutaneous oncology indications. Its lead product candidate, REM-001 Therapy, has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer ("CMBC"), who had previously received chemotherapy and failed radiation therapy. Completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

For more information, please visit www.AdgeroBiopharm.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.